RxDoctor Payments Data

Natasha Splaine-Talbott

Psychiatric/Mental Health · Sandpoint, IDNPI 1104191089

Payments from drug & device makers

$334in general payments, 2019–2025

Across 14 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$127
  • Teva Pharmaceuticals USA, Inc.$71
  • E.r. Squibb & Sons, L.L.C.$43
  • Sage Therapeutics, LLC$26
  • Otsuka America Pharmaceutical, Inc.$20
  • Sunovion Pharmaceuticals Inc.$18
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$334100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$334 in reported general payments places this provider in the 35th percentile of 221 psychiatric/mental health providers in Idaho.

See all psychiatric/mental health providers in Idaho

Medicare billing

Part B allowed, 2024
$19,038
Medicare patients
32
Services billed
211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate20$56,273
AristadaAripiprazole Lauroxil18$55,899
PerserisRisperidone12$34,226
Aripiprazole65$7,038
SeroquelQuetiapine Fumarate16$6,604
BelsomraSuvorexant13$5,773
Lurasidone Hcl22$4,419
Clozapine70$3,979
Atomoxetine Hcl11$3,526
Lamotrigine ErLamotrigine11$3,242
Quetiapine Fumarate181$2,352
Bupropion XlBupropion Hcl94$1,590
Ziprasidone Hcl31$1,513
Trifluoperazine Hcl12$1,383
Olanzapine66$1,342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Aristada$127$55,89918 claims
Indivior Inc.Perseris$17$34,22612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 221 psychiatric/mental health providers in Idaho.

Other psychiatric/mental health in Sandpoint

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →